Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the
society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) -
offers a cost-saving, home-based, user-friendly brain stimulation system that increased
6-month treatment retention of OUDs in a pilot study; and also, acutely reduced opioid
withdrawal severity and negative affect during induction into opioid maintenance therapy.
This study will establish its effectiveness in a broad category of OUD subjects at different
stages of OUD care continuum.
Phase:
Phase 2
Details
Lead Sponsor:
Evon Medics LLC
Collaborators:
Clinics of Dr. Edwin Chapman, MD, PC @ MHDG Family and Medical Counseling Service, Inc Howard University Maryland Treatment Centers @ ARTC National Institute on Drug Abuse (NIDA)